- Research works
- 45 ▲ 66% vs 2013–17
- Citations
- 677 15.0 per fractional work
- Top-10% rate
- 16.3% record average 16.5%
- Open access
- 50% world 28%
Not ranked overall: Hanall Biopharma (South Korea) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 12.1×. Every wedge is a field page.
- Immunology and Microbiology 12.1×
- Biochemistry, Genetics and Molecular Biology 5.9×
- Pharmacology, Toxicology and Pharmaceutics 4.6×
- Medicine 2.0×
- Nursing 1.6×
- Materials Science 1.1×
- Dentistry 1.1×
- Neuroscience 0.6×
- Computer Science 0.4×
- Engineering 0.4×
- Earth and Planetary Sciences 0.3×
- Agricultural and Biological Sciences 0.1×
Which keywords describe research at Hanall Biopharma (South Korea)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer, Immunotherapy, Tumor Microenvironment, Innate Immunity, Cancer Therapy, Transcriptional Regulation, Tumor Targeting and Cancer Immunotherapy.
- Epidemiology
- Immunity
- Nanoparticles
- Inflammation
- Cancer Therapy
- Immunotherapy
- Cancer
- Tumor Microenvironment
- Innate Immunity
- Transcriptional Regulation
- Cancer Immunotherapy
- Tumor Targeting
- Oxidative Stress
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 13 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 13 words, with their numbers
- Cancer2▲ 8.0×12 topics
- Immunotherapy2▲ 15×6 topics
- Tumor Microenvironment2▲ 17×5 topics
- Cancer Therapy2▲ 12×7 topics
- Innate Immunity2▲ 23×4 topics
- Inflammation1▲ 3.3×11 topics
- Transcriptional Regulation1▲ 43×4 topics
- Nanoparticles1▲ 5.0×5 topics
- Cancer Immunotherapy1▲ 39×3 topics
- Immunity1▲ 14×4 topics
- Tumor Targeting1▲ 34×3 topics
- Epidemiology1▲ 1.34×10 topics
- Oxidative Stress1▲ 3.1×5 topics
Which research topics does Hanall Biopharma (South Korea) publish most on?
By volume in 2022–2025: interferon and immune responses, Nanoplatforms for cancer theranostics, Immunotherapy and Immune Responses and Cancer-related gene regulation.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 interferon and immune responses Immunology 1 works
- 2 Nanoplatforms for cancer theranostics Biomedical Engineering 1 works
- 3 Immunotherapy and Immune Responses Immunology 1 works
- 4 Cancer-related gene regulation Molecular Biology 0 works
- 5 HER2/EGFR in Cancer Research Oncology 0 works
- 6 Cancer Immunotherapy and Biomarkers Oncology 0 works
- 7 RNA Interference and Gene Delivery Molecular Biology 0 works
- 8 Ferroptosis and cancer prognosis Pulmonary and Respiratory Medicine 0 works
- 9 Angiogenesis and VEGF in Cancer Molecular Biology 0 works
- 10 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Hanall Biopharma (South Korea)'s research output changed?
Output in 2018–2022 was 66% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Seoul
- Seoul National University
- Yonsei University
- Korea University
- Sungkyunkwan University
- Hanyang University
- Kyung Hee University
- Chung-Ang University
- Samsung (South Korea)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.